◆英語タイトル:Laurus Labs Ltd (LAURUSLABS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8140
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for anti-retroviral and Hepatitis C. Laurus Labs also provides active pharmaceutical ingredients for oncology and other therapeutic areas. The company manufactures ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. It also offers drug substance, analytical development and product development services. The company operates research and development, and drug substance manufacturing facilities in Hyderabad and Visakhapatnam. Laurus Labs is headquartered in Hyderabad, Telangana, India.
Laurus Labs Ltd (LAURUSLABS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Licensing Agreements 13
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Equity Offering 17
Laurus Labs Raises USD194 Million in IPO 17
Acquisition 18
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd – Key Competitors 19
Laurus Labs Ltd – Key Employees 20
Laurus Labs Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 22
Recent Developments 23
Financial Announcements 23
Nov 09, 2017: Laurus Labs Records Healthy Performance, PAT Grows at 19% in H1 FY I8 23
May 18, 2017: Laurus Labs Reports Revenue Of INR19.3 Billion In Fiscal 2018 25
Feb 09, 2017: Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO 26
Corporate Communications 27
Mar 08, 2018: Laurus Labs: Resignation of Executive Director 27
Mar 08, 2018: Laurus Labs Appoints Dr. Venkata Lakshmana Rao Chunduru as Executive Director 28
Mar 28, 2017: Laurus Labs Announces Resignation of Director 29
Jan 02, 2017: Laurus Labs: Resignation of Director 30
Legal and Regulatory 31
Mar 01, 2018: Laurus Labs Completes USFDA Inspection Of Unit 2 With No Observations- Zero 483 31
Nov 14, 2017: laurus labs recieves the EIR for its unit 1 & 3 32
Sep 15, 2017: Laurus Labs Recivces the EIR from UFDA, and also Successfully Completes of the German Regulatory Authority for Unit-2 and WHO inspections for Unit-3 API Facilities 33
Aug 18, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection for Unit-1 and Unit-3 API Facilities 34
May 19, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Laurus Labs Raises USD194 Million in IPO 17
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd, Key Competitors 19
Laurus Labs Ltd, Key Employees 20
Laurus Labs Ltd, Other Locations 21
Laurus Labs Ltd, Subsidiaries 21
Laurus Labs Ltd, Joint Venture 22
List of Figures
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8